Arthritis, Rheumatoid Clinical Trial
Official title:
A Prospective Cohort Study in 6 Swiss Rheumatology Centres and 4 Travel Clinics on the Immunogenicity and Safety of Tetanus and Hepatitis A Vaccine in Patients With Rheumatoid Arthritis, Axial Spondyloarthritis and Vasculitis and Healthy Controls
Backgound and relevance of the project:
Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are at increased risk of
contracting infections. The increased risk can be attributed to the immunological disorder
itself, as well as to the immunosuppressive treatment. Vaccination against many infections
is recommended in this patient group. However, the immunogenicity of vaccines may be reduced
and may also be influenced by the administered treatment. Potential reactivation of the
underlying disease triggered by vaccination is another important concern.
From the patients' and public health perspectives, an important task of physicians is giving
advice on vaccines. Completing this task is often difficult, because data on the
immunogenicity and safety of vaccines in these patient groups are scarce, especially with
regard to treatment with new immunosuppressive medications, such as biological agents.
Lastly and importantly, due to new therapeutic options, health among AIIRD patients has
considerably improved and an increasing number of patients undertake overseas travel
activities requiring additional vaccinations. In this context, reliable advice with regard
to vaccinations is almost impossible, because for most travel vaccinations the
immunogenicity and safety profile is unknown.
Research addressing the immunogenicity and safety of vaccines in different autoimmune
inflammatory diseases treated with different immunosuppressive medications is urgently
needed to allow giving evidence based vaccine advice.
In this observational study the immunogenicity and safety of tetanus booster and hepatitis A
vaccinations will be assessed in AIIRD patients. The immune response will be evaluated as a
function of the underlying disease and the possible influence of commonly used
immunosuppressive drugs on the immune response will be studied.
Rationale for studying tetanus booster and hepatitis A vaccine Tetanus vaccination is one of
the most frequently recommended vaccinations, and the effect of a booster vaccination can be
addressed. Hepatitis A vaccine is the most widely used travel vaccine. Despite their
importance, only very limited data are available for tetanus and hepatitis A vaccine in this
patient group. By focusing on these vaccines the study will lead the way to the evaluation
of further vaccines.
The purpose of this study is to determine whether tetanus and hepatitis A vaccinations are
as immunogenic and safe in AIIRD patients as in healthy controls.
The study will be placed in 6 rheumatology clinics in Switzerland and in 4 travel medicine clinics. Consecutive subjects with rheumatoid arthritis, spondylarthritis (ankylosing spondylitis), vasculitis (ANCA associated vasculitis and Behçet's disease) and healthy controls will be recruited. ;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
| Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
| Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
| Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
| Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
| Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
| Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
| Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
| Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
| Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
| Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
| Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
| Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
| Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
| Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
| Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
| Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 | |
| Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 |